ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 289

Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis

Rhina Castillo1, Suhas M. Radhakrishna2, Andreas O. Reiff3 and Katherine AB Marzan1, 1Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 2Pediatric Rheumatology, Kaiser Permananete Medical Group, Oakland, CA, 3Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Abatacept, Pediatric rheumatology and systemic lupus erythematosus (SLE)

Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Nephritis (LN) in pediatric systemic lupus erythematosus (pSLE) requires treatment (tx) with corticosteroids (CS) and other agents such as mycophenolate mofetil (MMF) or cyclophosphamide (CYC). However, some patients (pts) fail standard therapy leaving physicians with few options. Although a recent phase II randomized controlled combination trial of abatacept and MMF (ABA+MMF) in adult SLE did not meet its endpoints, we examined if this combination therapy may have a therapeutic benefit in pSLE pts with refractory LN.

Methods:

We performed a retrospective observational study in 5 pSLE pts with class IV and V lupus nephritis. All pts were treated with ABA+MMF after  previous treatment and failure or intolerance to CYC and MMF with concomitant CS. Data collected included demographics, disease duration, renal histology and medications used. SLE Disease Activity score (SLEDAI) including parameters of systemic and renal disease activity were assessed at baseline and after 12 weeks of each tx.

Results:

Pt age at diagnosis was 9-15years (mean 12.6 ± 2.3). Average disease duration was 22-97 months (mo) (mean 52.8 ± 30.8), before ABA+MMF therapy was started.  Two pts had class IV, 1 pt had class V and 2 pts had class IV/V LN.  

All 5 pts had a statistically significant decrease in their SLEDAI scores and successfully had their steroid dose reduced while on ABA+MMF. One pt achieved complete remission and 3 pts were completely weaned off steroids after an average of 9 mo (3-16mo). Repeated ANOVA analyses comparing SLEDAI scores at baseline and after 12 weeks of CYC, MMF and ABA+MMF respectively, showed a statistically significant pattern of change from the baseline score with each change in therapy (P<0.0001). Paired comparison of SLEDAI scores on each drug to baseline scores showed the most significant improvement with combination therapy (MMF+ABA p=0.0001, CYC p=0.0199, MMF p=0.0520).

Conclusion:

The above data suggests that combination therapy with ABA+ MMF can be superior to MMF alone and may be an effective option in refractory pSLE nephritis, raising the possibility of a synergistic effect between the two drugs.  Additional studies are needed in pSLE to further assess the efficacy of this combo tx.


Disclosure:

R. Castillo,
None;

S. M. Radhakrishna,
None;

A. O. Reiff,
None;

K. A. Marzan,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mycophenolate-mofetil-and-abatacept-combination-therapy-in-refractory-pediatric-systemic-lupus-erythematosus-nephritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology